Literature DB >> 22999131

Modeling using discrete event simulation: a report of the ISPOR-SMDM Modeling Good Research Practices Task Force--4.

Jonathan Karnon1, James Stahl, Alan Brennan, J Jaime Caro, Javier Mar, Jörgen Möller.   

Abstract

Discrete event simulation (DES) is a form of computer-based modeling that provides an intuitive and flexible approach to representing complex systems. It has been used in a wide range of health care applications. Most early applications involved analyses of systems with constrained resources, where the general aim was to improve the organization of delivered services. More recently, DES has increasingly been applied to evaluate specific technologies in the context of health technology assessment. The aim of this article was to provide consensus-based guidelines on the application of DES in a health care setting, covering the range of issues to which DES can be applied. The article works through the different stages of the modeling process: structural development, parameter estimation, model implementation, model analysis, and representation and reporting. For each stage, a brief description is provided, followed by consideration of issues that are of particular relevance to the application of DES in a health care setting. Each section contains a number of best practice recommendations that were iterated among the authors, as well as among the wider modeling task force.
Copyright © 2012 International Society for Pharmacoeconomics and Outcomes Research (ISPOR). Published by Elsevier Inc. All rights reserved.

Entities:  

Mesh:

Year:  2012        PMID: 22999131     DOI: 10.1016/j.jval.2012.04.013

Source DB:  PubMed          Journal:  Value Health        ISSN: 1098-3015            Impact factor:   5.725


  71 in total

Review 1.  Including adverse drug events in economic evaluations of anti-tumour necrosis factor-α drugs for adult rheumatoid arthritis: a systematic review of economic decision analytic models.

Authors:  Eleanor M Heather; Katherine Payne; Mark Harrison; Deborah P M Symmons
Journal:  Pharmacoeconomics       Date:  2014-02       Impact factor: 4.981

2.  Value of a Hypothetical Pharmacogenomic Test for the Diagnosis of Statin-Induced Myopathy in Patients at High Cardiovascular Risk.

Authors:  Dominic Mitchell; Jason R Guertin; Jacques LeLorier
Journal:  Mol Diagn Ther       Date:  2018-12       Impact factor: 4.074

3.  Decision-analytic models: current methodological challenges.

Authors:  J Jaime Caro; Jörgen Möller
Journal:  Pharmacoeconomics       Date:  2014-10       Impact factor: 4.981

4.  Resource modelling: the missing piece of the HTA jigsaw?

Authors:  Praveen Thokala; Simon Dixon; Beate Jahn
Journal:  Pharmacoeconomics       Date:  2015-03       Impact factor: 4.981

5.  Simulation as an ethical imperative and epistemic responsibility for the implementation of medical guidelines in health care.

Authors:  Luciana Garbayo; James Stahl
Journal:  Med Health Care Philos       Date:  2017-03

6.  Avoiding and identifying errors and other threats to the credibility of health economic models.

Authors:  Paul Tappenden; James B Chilcott
Journal:  Pharmacoeconomics       Date:  2014-10       Impact factor: 4.981

Review 7.  Cost-effectiveness analyses in multiple sclerosis: a review of modelling approaches.

Authors:  Shien Guo; Christopher Pelligra; Catherine Saint-Laurent Thibault; Luis Hernandez; Anuraag Kansal
Journal:  Pharmacoeconomics       Date:  2014-06       Impact factor: 4.981

Review 8.  Challenges in modelling the cost effectiveness of various interventions for cardiovascular disease.

Authors:  Laura T Burgers; William K Redekop; Johan L Severens
Journal:  Pharmacoeconomics       Date:  2014-07       Impact factor: 4.981

9.  Discretely Integrated Condition Event Simulation for Pharmacoeconomics.

Authors:  Mondher Toumi; Ekkehard Beck; Steve Sherman; Leyla Mohseninejad; Samuel Aballéa
Journal:  Pharmacoeconomics       Date:  2016-11       Impact factor: 4.981

10.  Cost-Effectiveness of Remote Cardiac Monitoring With the CardioMEMS Heart Failure System.

Authors:  Jordana K Schmier; Kevin L Ong; Gregg C Fonarow
Journal:  Clin Cardiol       Date:  2017-03-08       Impact factor: 2.882

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.